sovietknuckles
Now
•
100%
"A recent poll reveals that more UK residents believe that Hamas, Iran, or Hazbollah are to blame for the conflict than do Israel"
sovietknuckles
Now
•
100%
What does this mean?
#1 – Denial – Pretending a problem does not exist to provide artificial relief from anxiety.
Citing excess mortality without adjusting for survivorship bias.
I found this article:
- Accelerated deaths and survivorship bias: The excess deaths directly attributed to COVID-19 are most likely not realized in a world without COVID-19. In other words, they are carried forward, or accelerated, from expected deaths in the future. This rate of acceleration largely depends on, firstly, the percentage of excess COVID-19 deaths, which depends on the duration and severity of the pandemic, and, secondly, the mortality risk differential in factors such as age, gender, and socio-economic status. All else being equal, accelerated deaths may bring forth lower than expected mortality rates, or “negative” excess deaths, in the future.
So they're saying that because COVID kills the most vulnerable people first, future excess deaths will be decreased as a result because so many of the vulnerable people are already dead?
sovietknuckles
Now
•
100%
The bright side to electing ancient presidents is that they don't get as long to be rehabilitated
sovietknuckles
Now
•
100%
A real leader would have caught the shoes with their face and say "Shoe, coward! You are only going to fit a man"
sovietknuckles
Now
•
100%
economists
Suddenly it all lines up
sovietknuckles
Now
•
100%
guys literally only want one thing and it's fucking disgusting
sovietknuckles
Now
•
100%
Pfizer doesn't make the vaccines, BioNTech does. Pfizer just owns BioNTech, and Pfizer would only advertise the COVID vaccines if they think COVID vaccines are more profitable than the other products that Pfizer sells.
It looks like they think being unvaccinated against COVID is more profitable
sovietknuckles
Now
•
100%
What's the point of passing the bill if they're not willing to override the veto? They're just letting Gavin Newsom be the spoiler, even though others would step up to spoil if he did not
sovietknuckles
Now
•
100%
i.e. no one masks anyway, might as well do what appeals to them instead of advocate militantly for what should be done — and that just really bums me out.
I think that's that's the target audience, people who can't or won't mask. My parents won't mask when out of the house unless I'm there watching them, for example, and sometimes not even then. If your job won't let you mask or makes it difficult, nasal sprays can help in that case, too.
For maskers like myself, it's particularly useful in airport security, where they make me take off my mask for identification, and airport terminals and airplanes, where I might want to eat but there's a lot of other people around.
sovietknuckles
Now
•
100%
plus they couldn't find a mask that works with their glasses
Most KN95s and all N95s I have tried fog my glasses. But ProGear N95s don't, that's the kind that I prefer. Once you put it on, you can press the metal nose band to fit it to your exact nose shape
But I've also read enough anecdotal reports from people who use them and still got sick with covid. Who knows if they were properly applied,
Maybe it's important to get one with a good spray. The Betadine iota carrageenan spray is very good, with respect to diffusion. It also doesn't require shaking or spraying beforehand to get a full spray.
Some Covixyl bottles don't diffuse the spray well, and it's very noticeable
but I doubt these sprays alone will do much if your exposure levels are high.
And if there's enough COVID in the air, you can get COVID in your eyes, not just your nose. Wearing Stoggles helps if someone coughs in your direction, but not if there's just lots of COVID in the air
sovietknuckles
Now
•
100%
sovietknuckles
Now
•
100%
Is their health insurance Kaiser? Never do Kaiser if you can help it, especially if you can get a PPO instead. A Kaiser PPO does not count
This mucosal/nasal vaccine is called MPV/S-2P and it is developed by the NIH's National Institute of Allergy and Infectious Diseases (NIAID). From a [2023 study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543296/): > A single dose of MPV/S-2P was highly immunogenic, and a second dose increased the magnitude and breadth of the mucosal and systemic anti-S antibody responses and increased levels of dimeric anti-S IgA in the airways. Obviously don't dox yourself on Hexbear, but the phase 1 trial sites are: :::spoiler Decatur, Georgia The Hope Clinic of Emory University ::: :::spoiler Mineola, New York, United States NYU Grossman Long Island School of Medicine - Vaccine Center ::: :::spoiler Houston, Texas, United States Baylor College of Medicine ::: so if you live near one of those, maybe you can participate. They want to enroll 60 people, no clue how close they are to that goal To try to enroll, [contact them](https://clinicaltrials.gov/study/NCT06441968?term=NCT06441968&rank=1&tab=table) by phone or email.
sovietknuckles
Now
•
100%
What is the original URL? I don't want to fill out a captcha just to see what the URL of the posted article was
sovietknuckles
Now
•
100%
It means that the key to getting a company to ditch arbitration is for enough people to win individual arbitration cases. There's arbitration lawyers who hedge their whole careers on arbitration payouts
sovietknuckles
Now
•
100%
Apparently the company calls it Profi and it's already for sale for
$25 per bottle
but with a 15-25% discount if you do a subscription instead of a 1-time purchase. The amount of discount depends on how frequent your subscription is, though maybe you can just choose the most often one and cancel immediately anyway
Its ingredient list: pectin, gellan, phenylethyl alcohol, polysorbate 80, benzalkonium chloride, purified water
They say that it can be used up to 3 times per day but that there should be at least a 4-hour gap between uses
Their site's Read the Science link takes you to the paywalled paper
sovietknuckles
Now
•
100%
I don't know how saline gel nasal sprays compare, but of existing nasal sprays, carrageenan (80% risk reduction) > hypromellose (78% risk reduction) > nitric oxide (75% risk reduction) > xylitol (62% risk reduction) according to the Clean Air Club, so nasal sprays aren't all just the same thing.
sovietknuckles
Now
•
100%
For recovery from long COVID, one user from r/covidlonghaulers who recovered thought in 2022 that long COVID is result of too much glutamate, and more recent studies support that hypothesis (for example, see this review). Normally, your body is supposed to convert glutamate to GABA, but under this theory, long COVID patients struggle to convert all of their glutamate, resulting in brain fog.
That poster thinks that magnesium and iron are key. From a 1-year follow-up after that:
-
Magnesium, in various forms (see their follow-up post for details). The form of magnesium that crosses the blood-brain barrier most easily is magnesium threonate, but it's patented by a bazinga company that licenses its patent out to to supplement companies, so this form is far more expensive than other forms of magnesium. Other magnesium supplements are probably fine.
-
Iron, if you're iron-deficient. A ferritin lab will tell you this.
Even if you're doing everything right, it will probably take months and months at the very least to recover, though hopefully you'll notice a difference sooner than later.
They also suggest DLPA as a shorter-term crutch, since magnesium and iron take longer to help regulate your glutamate.
www.eurekalert.org
The spray is called "Pathogen Capture and Neutralizing Spray" (PCANS) for now > This data suggest PCANS as a promising daily-use prophylactic against respiratory infections. [The study](https://onlinelibrary.wiley.com/doi/10.1002/adma.202406348) is paywalled, and the abstract doesn't list its ingredients beyond > The formulation consists of excipients identified from the FDA's Inactive Ingredient Database and Generally Recognized as Safe list to maximize efficacy for each step in the multi-modal approach. Based on that description, its ingredients might not be very different from Covixyl, though it claims to be much more effective. Edit: Apparently its already for sale, I included some details in [a comment](https://hexbear.net/comment/5436030)
sovietknuckles
Now
•
100%
I use both platforms, and I know of several leftist Rumble channels (Syrianalysis, Richard Medhurst, Danny Haiphong, Geopolitical Economy Report). Does that disprove your claims [...]?
Sure it does, I hadn't heard of any of those. I'm glad you found leftist channels on Rumble. I, personally, would be very hesitant to point someone to Rumble (or Twitch) in general, rather than to specific channels, whether they're on Rumble or Twitch.
sovietknuckles
Now
•
100%
You seem to be responding to the first sentence of my comment with no comprehension of everything else in my comment.
If you think that there is no capacity of leftist infiltration on Twitch, you're wrong (see: all of the leftist streamers I listed above). And if you think that Rumble has any potential to harbor leftist content, you are wrong again.
sovietknuckles
Now
•
100%
in the quantum cloud
https://xcancel.com/nytopinion/status/1829879853165765055 https://archive.ph/lxKBc https://www.nytimes.com/2024/08/31/opinion/heat-wave-air-conditioning-climate-change.html
Don't bother with opsec, I printed them off in high DPI
[CW: Vox]
https://www.bloomberg.com/news/articles/2024-08-08/microsoft-palantir-team-up-to-sell-ai-to-us-defense-intelligence-agencies
> This month, there are some clinical results for a mucosal next generation Covid vaccine – the 30th mucosal vaccine on my list of mucosal vaccines that have gone into clinical trial. Plus, I’ve added over a dozen preclinical reports to my collection, including more results showing prevention of transmission or durable immunity. And an intranasal vaccine based on an agent called a STING agonist showed strong protection from other coronaviruses, as well as protection against transmission. > > :::spoiler News from US Project NextGen > As well as funding trials of next generation Covid vaccines, Project NextGen is funding research on the correlates of protection from authorized vaccines (studying levels of antibodies etc associated with effective vaccination). To try to ensure a group of participants that is more diverse than is usual for clinical trials based in hospitals and universities, [they announced this month](https://aspr.hhs.gov/newsroom/Pages/Project-Walgreens-23July2024.aspx) a pharmacy-based initiative to broaden access. About 20 Walgreens pharmacies in urban, suburban, and rural areas will be clinical trial sites, and “To recruit study volunteers, Walgreens will provide information on how and where to participate in the study.” > > This decentralized trial will also get technical and other support from the Fred Hutch Cancer Center – and the Center has [also been funded](https://medicalcountermeasures.gov/newsroom/2024/fhcc/) to support some of the next generation vaccine trials. > > In other Project NextGen news, Castlevax – who will be running one of the phase 2b “mini-efficacy” trials for their intranasal vaccine – [announced](https://www.businesswire.com/news/home/20240730713002/en/CastleVax-Inc.-Receives-34-Million-from-BARDA-to-Continue-Advancing-Intranasal-NDV-based-COVID-19-Vaccine-into-Phase-2b-Clinical-Efficacy-Testing) they received additional funding for that trial. > > Finally, last update, [I reported](https://absolutelymaybe.plos.org/2024/06/30/a-mini-surge-of-clinical-trials-and-advances-for-people-with-immunosuppression-nextgen-covid-vax-update-18/#mucosal) that a mucosal vaccine developed by the NIH’s NIAID was entering a phase 1 trial. Soon after, [the NIH announced](https://www.nih.gov/news-events/news-releases/nih-sponsored-trial-nasal-covid-19-vaccine-opens) that recruitment had begun, and that this was the first Project NextGen-funded clinical trial. > ::: > > :::spoiler Mucosal vaccine news > This month, I added a 30th mucosal vaccine that has gone into clinical trial. (I missed this one when it went into [a clinical trial in China last year](https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2300070346).) It’s an intranasal viral vector vaccine called Ad5-S-Omicron BA.1, based on adenovirus 5, and Omicron. The developers [reported some results](https://www.nature.com/articles/s41392-024-01906-0) for 8 people in the phase 1 trial, along with a transmission study in mice. > > The people in the clinical trial had been vaccinated with other vaccines at least 6 months before getting 2 doses of nasal spray. The developers tested their people’s blood and nasal fluids to see if they showed signs of immune response to new Omicron variants. > > Nasal immunoglobulin, they reported, “retained potent neutralization” against all the Covid variants they tested, though serum immunoglobulins did not for all of them. > > The developers then tested the impact on mice of intranasal application of the vaccinated people’s immunoglobulin. There were 4 groups of mice getting different immunoglobulin, and a control group getting immunoglobulin from people who did not have the intranasal vaccine. The mice getting the vaccinated people’s nasal immunoglobulin “showed a significant and comparable reduction in viral load.” > > *More new preclinical results:* > > I’ve added 7 preclinical reports on results for another 5 mucosal vaccines to my collection since the last update, with one reported below in the pancoronavirus vaccine category. The others include: > > * Tokyo Metropolitan Institue of Medical Science and Toko Yakuhin Kogyo Co (Japan): This vaccine is a protein subunit mixed with carboxyvinyl polymer (CVP), [tested](https://www.mdpi.com/2076-393X/12/7/794) intranasally in mice. The developers reported levels of longterm efficacy (at least 15 months). > > * Friedrich Loeffler Institute (Germany) and University of Bern (Switzerland): [This report](https://www.nature.com/articles/s41564-024-01755-1) is for genome-modified live-attenuated vaccines, tested as a single intranasal dose in mice and hamsters. For one of them, unimmunized hamsters put in contact with immunized animals after a Covid challenge test had minimal viral RNA in nasal washings and no signs of the virus in organs. > > * Ohio State University (USA): This group developed several versions of viral vector vaccine based on 3 Covid variants. The viral vectors were measles and mumps components of the MMR vaccine. [The developers reported](https://www.nature.com/articles/s41467-024-49443-2) on testing these intranasally in mice and hamsters. > ::: > > :::spoiler Pancoronavirus vaccine news > Pancoronavirus vaccines aim to provide protection not only from variants of the SARS virus that causes Covid, but also against the next new coronavirus to spread among humans. This month, 3 vaccines have joined this category, all from the US. > > *NanoSTING-SN: A mucosal protein subunit vaccine from the University of Houston and Auravax (USA)* > > NanoSTING is the name for a mucosal adjuvant that is a STING agonist, a class of agents that can stimulate immune activity. (STING stands for stimulator of interferon genes.) Different versions of this vaccine [were tested](https://www.nature.com/articles/s41467-024-50133-2) in mice and hamsters. > > Hamsters got 2 intranasal doses of the SN version, and then had a challenge test with the Delta variant, along with an unvaccinated group. The vaccinated hamsters had reduced viral loads, and by day 6, no virus was detectable. > > The developers did a transmission study using the SN version in hamsters. One group had sham immunization, and a group of 8 hamsters had 2 intranasal doses of SN, 21 days apart. The immunized hamsters were challenged with an Omicron variant on day 35, and a day later, each was co-housed with an unimmunized hamster. > > The vaccine protected the 8 hamsters from getting sick, and only 2 showed a low amount of virus in lung and nasal tissue. No virus was detected in any of the contact hamsters. The experiment was repeated with a single intranasal dose: This also prevented transmission. > > The developers tested blood from mice vaccinated with the SN version and found signs of immune response to a group of other coronaviruses, including the original SARS and MERS, as well as an alphacoronavirus. > > Then, a group of vaccinated and unvaccinated mice were challenged with the original SARS. The unvaccinated mice showed signs of illness, but the vaccinated ones did not, and all survived. > > Finally, the developers vaccinated 3 primates (rhesus macaques) with 2 intranasal doses, 28 days apart. Signs of immune response were consistent with those of the mice. > > This is the fourth preclinical report for this vaccine – all records here. > > *A protein subunit vaccine from Georgia State University (USA)* > > Four versions of this vaccine were tested. One of them, based on the Delta variant, showed signs of protection from all the Covid variants tested. Immunized mice were also protected in challenge experiments with the Delta variant, and the original SARS. > > This is the second preclinical report for this vaccine – the first is here. > > *A protein subunit vaccine from Baylor College of Medicine (USA)* > > This vaccine aims to provide protection from betacoronaviruses, and is based on components of the original SARS, MERS, and an Omicron variant. The vaccine was [tested in mice](https://www.nature.com/articles/s41541-024-00924-x). The mice showed signs of response to all of those viruses, as well as betacoronaviruses that are currently only infecting bats. > :::
> The final update of the NIH COVID-19 Treatment Guidelines was on February 29, 2024. PDFs of the Guidelines can be downloaded until August 16, 2024, when the website will be shut down. Not that the site was very good. Their *Prevention of SARS-CoV-2 Infection* page mentions masks once on the whole page and does not mention nasal sprays: > The risk of SARS-CoV-2 transmission can be reduced by covering coughs and sneezes, wearing a well-fitted mask around others, and isolating when experiencing symptoms. Frequent handwashing also effectively reduces the risk of infection. > Vaccination is the most effective way to prevent COVID-19. [Older versions](https://files.covid19treatmentguidelines.nih.gov/guidelines/archive/covid19treatmentguidelines-10-27-2021.pdf) of their PDF mention N95s. The only mention of N95s, other than recommending them for healthcare workers, is to claim that surgical masks are just as good: > There is evidence from studies of viral diseases, including SARS, that both surgical masks and N95 respirators reduce the risk of transmission.6 Moreover, surgical masks are probably not inferior to N95 respirators for preventing the transmission of respiratory viral infections; a recent systematic review and meta-analysis of randomized controlled trials that compared the protective effects of medical masks and N95 respirators demonstrated that the use of medical masks did not increase the incidence of laboratory- confirmed viral respiratory infections (including coronavirus infections) or clinical respiratory illness. (That is incorrect.) The [latest version](https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf) does not mention the existence of N95s or KN95s, it just says "a well-fitted mask". And N95s and KN95s are not mentioned on the site itself, outside of these PDFs.
www.youtube.com
Evangelical Christians are the largest pro-Israel lobby in the US
absolutelymaybe.plos.org
> Mucosal vaccines go directly into the mucosal tissue where infection begins – for example, intranasally or via tablets. If they could induce strong enough mucosal immunity, such vaccines could reduce the risk of infection and transmission. That’s often called “sterilizing” immunity. > > Development of these vaccines has just received a massive boost. A global consortium is being funded to develop and then run human challenge trials of intranasal or inhaled vaccines in a program called MusiCC. A human challenge trial – where participants are quarantined and deliberately infected in that controlled environment – could find out quickly and definitively establish whether or not particular vaccines can prevent infection and transmission. If very effective vaccines are tested in this program, it would vault them rapidly through development stages that could otherwise take years. > > As well, the US Government’s Project NextGen is calling for interest in developing and/or supporting oral Covid vaccines. This pair of new initiatives kick off this month’s update. > > There is also some news from clinical trials for 2 intranasal vaccines, as well as development news on 2 vaccines in the “variant-proof” category, and several preclinical studies. :::spoiler New development initiatives for mucosal vaccines > In the last few weeks, 2 initiatives aiming to boost the development of mucosal vaccines have been announced – a global human challenge trial program to be led by Imperial College London for inhaled and intranasal vaccines, and a request from US Project NextGen for parties interested in developing or supporting oral Covid vaccines. > > ***Human challenge program: Mucosal Immunity in human Coronavirus Challenge (MusiCC)*** > > This is a new 5-year program led by Imperial College London to speed development and access to mucosal coronavirus vaccines by running placebo-controlled human challenge trials. That involves trying to infect volunteers under controlled conditions, which means trials that can establish whether infection is blocked can be completed quickly, with fewer volunteers than a standard trial. > > MusiCC is supported with $57 million from the European Union and CEPI (Coalition for Epidemic Preparedness Innovations). A global consortium of more than a dozen teams and organizations specializing in human challenge studies will be involved. They are interested in inhaled and intranasal vaccines that could block transmission of betacoronaviruses (the virus group including Covid and MERS). The program “includes a commitment that any vaccines developed are made available first and at an affordable price to the most vulnerable populations.” > > [From the announcement](https://cepi.net/global-consortium-plans-coordinated-human-challenge-studies-hunt-transmission-blocking-coronavirus): “Using harmonised standard operating procedures, the trials will take place across several sites in the UK, Europe, the United States and Singapore and will each involve a small group of young, healthy volunteers. In the challenge trial, volunteers will first receive either a dose of an investigational vaccine designed to provide mucosal coronavirus immunity or placebo before being intentionally exposed to a calibrated dose of SARS-CoV-2. A model using a seasonal coronavirus called OC43 is also being developed for similar use.” > > The first step is deciding on which variant of SARS-CoV-2 will be used, and then developing a version that can be used in the trials. Imperial College London has done this before. Their team [published the results](https://www.nature.com/articles/s41591-022-01780-9) of a Covid human challenge trial with 36 people to test the process. They were able to infect just over half the participants with a version of the original virus (wild type). > > The [UK government provided](https://www.bbc.com/news/health-54612293) funding for that original program, which was announced in October 2020. The trial got the regulatory green light to start [in February 2021](https://www.theguardian.com/world/2021/feb/17/uk-to-begin-worlds-first-covid-human-challenge-study-within-weeks?CMP=share_btn_tw), and the first participants had left quarantine [by March](https://www.imperial.ac.uk/news/218294/first-volunteers-covid-19-human-challenge-study/). The government funding for the whole program of which that trial was part, was £33.6 million – in pounds sterling for comparison, this new program is £44 million. > > We don’t know yet which vaccines might be involved. Other than Imperial College London, the only other organization named in CEPI’s announcement is University of Antwerp’s [Vaccinopolis](https://www.uantwerpen.be/en/research-groups/centre-for-evaluation-vaccination/vaccinopolis/). [A statement](https://www.imperial.ac.uk/news/251961/global-human-challenge-consortium-push-next/) from Imperial College London mentions a London hub for trials, and studying the biology of respiratory infection with the [National Centre for Infectious Diseases (NCID) in Singapore](https://www.ncid.sg/About-NCID/Pages/default.aspx). ::: :::spoiler New preclinical results for mucosal vaccines > I’ve added 3 preclinical reports on results for mucosal vaccines to my collection since the last update: > > - *Vaxart (USA)*: This is a viral vector vaccine, and a tablet form is one of the vaccines with Project NextGen funding for a phase 2 trial. The latest study tested 3 versions of the vaccine intranasally in primates, and included a group that received an injection and an intranasal dose. (Records in my collection for this vax here.) > > - *Chengdu Kanghua Biological Products (China)*: This is also a viral vector vaccine. A study tested an intranasal version in mice, as standalone vaccine or booster. > > - *Osaka University (Japan)*: This live attenuated virus vaccine was tested in intranasally in hamsters. :::
 is only half of the story
absolutelymaybe.plos.org
> The race for next generation vaccines is steadily heating up now. And this month, we’ve passed a major milestone: The first data suggesting that an already-authorized nextgen vaccine could outperform the BNT/Pfizer vaccine – with its manufacturers ramping up production facilities for potentially wide distribution in the next year or so. > > Most vaccines that reach first-in-human trials [don’t make it](https://academic.oup.com/biostatistics/article/20/2/273/4817524) all the way to major regulator approval. The odds improve, though, for those that make it to mid-stage trials (phase 2). On top of that, there’s a lot of variation in effectiveness between vaccines – so a good range of approaches reaching that mid-stage increases the odds of having much better vaccines. > > Though it’s not going at the blistering pace of the early pandemic, the scene is encouraging now. The number of next generation vaccines moving past first-in-human trials is into double digits. With another 2 pancoronavirus vaccines starting clinical trials this month, there’s even a handful of vaccines reaching the early stage at least in this tough category. And the body of clinical evidence seems to be growing steadily, too: We’ve been getting at least some results for an average of 2 clinical trials a month for the last 6 months. > > It’s still early days in many ways, though. Even for late-stage trials, most of the efficacy data is for signs of immunity only. We don’t know critical things, especially whether or not there will be mucosal vaccines that can make a major – and lasting – impact on getting and transmitting infection in people. But at least it looks as though more durable boosters are on the horizon. > > There’s a lot to get to this month for all types of vaccines, including news from clinical trials for 3 vaccines. This update starts with news from Project NextGen, with funding for another mini-efficacy trial for a mucosal vaccine. After that, I have recent results broken down into 3 categories of next-generation Covid vaccines ([definitions below](https://absolutelymaybe.plos.org/2024/02/23/picking-up-steam-next-generation-covid-vaccine-update-14/#definitions)). :::spoiler News from US Project NextGen > A fourth vaccine received funding in late January – for a phase 2b clinical trial for the oral vaccine [from Vaxart](https://investors.vaxart.com/news-releases/news-release-details/vaxart-receives-927-million-barda-project-nextgen-award-prepare). As with the others, the trial is to be for 10,000 participants. This vaccine has released [phase 1](https://www.medrxiv.org/content/10.1101/2022.07.16.22277601v1) trial results, as well as a press release for [phase 2](https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-positive-top-line-phase-ii-clinical-study-data) in 2022. The vaccine was later adapted for variants, and it was [reportedly](https://www.proactiveinvestors.co.uk/companies/news/1009235/hvivo-manufactures-omicron-human-challenge-study-1009235.html) on hold as they were developing a pancoronavirus vaccine. (Records in my collection for this vax [here](https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/VXA-CoV2-1%20-%20Vaxart/library).) > > This brings the number of Project NextGen-funded trials to 5. ::: :::spoiler New preclinical results for mucosal vaccines > I’ve added 7 preclinical reports on results for mucosal vaccines to my collection since the [last update](https://absolutelymaybe.plos.org/2024/01/11/a-major-first-next-generation-covid-vaccine-could-there-be-more-in-2024-update-13/). These include: > > - *sCPD9 from RocketVax and Freie Universität Berlin*: This is an intranasal live-attenuated vaccine. [This study](https://www.nature.com/articles/s41467-024-45348-2) tested the effectiveness of preventing transmission of strains of Omicron among non-primates, comparing the intranasal RocketVax vaccine to the BNT/Pfizer vaccine. > - *Ad5.SARS-CoV-2-S1 from Gaphas Pharmaceutical and University of Pittsburgh*: This is an intranasal viral vector vaccine. [This study](https://www.biorxiv.org/content/10.1101/2024.02.05.578925v1) tested an Omicron-adapated booster in non-primates. > - *ChAd-SARS-CoV-2-BA.5-S from Washington University of St Louis (USA)*: [This study](https://www.nature.com/articles/s41590-024-01743-x) includes versions of the intranasal viral vector vaccine further developed by Bharat Biotech in India and authorized there as iNCOVACC, tested in non-primates: An adaptation for the BA.5 strain of Omicron, compared to the original form, the adapted version alone, and a bivalent version (including both). > - *Unnamed vaccine from Pennsylvania State University (USA)*: This is an intranasal protein subunit vaccine, [studied](https://journals.asm.org/doi/10.1128/spectrum.04998-22) in non-primates. :::
citationsneeded.libsyn.com
> In this News Brief we are joined by friend of the show, [Maximillian Alvarez](https://therealnews.com/author/maximillian-alvarez) of [The Real News](https://www.youtube.com/user/therealnews), to discuss Democrats' pathetic, myopic, and nihilistic attempt to play the Racist Reverse Uno Card on Congressional Republicans.
I warned you
What I did: Tried embedding the image from [this post](https://toots.matapacos.dog/@theCommunistCenter/111763957593720910) on Hexbear: `` Expected result: Image is embedded Actual result:  More info: These hosts are whitelisted for embedding images on Hexbear: - chapo.chat - discuss.tchncs.de - hexbear.net - i.imgur.com - jlai.lu - lemm.ee - lemmy.ml - lemmy.world - lemmygrad.ml - mander.xyz - pathfinder.social - possumpat.io - test.hexbear.net - toots.matapacos.dog - ttrpg.network - www.hexbear.net But in the case of `toots.matapacos.dog`, `assets.toots.matapacos.dog` should be whitelisted instead.
Interview starts at 4:08:02 in [the VOD](https://www.twitch.tv/videos/2034536667?t=4h8m2s) Context: Media is putting out articles like https://www.vice.com/en_us/article/epv74k/everything-we-know-about-timhouthi-chalamet-the-yemeni-influencer-celebrating-red-sea-ship-raids , so Hasan talked to him directly Important: Hasan asks if he knows what One Piece is https://clips.twitch.tv/ExcitedSparklyRamenWoofer-Kdnimydpec0yxUYR
Now